Logo
x

Search

Subscribe Now

enGene

enGene to go Public via Forbion European Acquisition Corp. SPAC Merger for ~$135M

enGene to go Public via Forbion European Acquisition Corp. SPAC Merger for ~$135M

  • May 19, 2023
enGene Reports Preliminary Results of EG-70 in P-I/II (LEGEND) Trial for the Treatment of Non-Muscle Invasive Bladder Cancer

enGene Reports Preliminary Results of EG-70 in P-I/II (LEGEND) Trial for the Treatment of Non-Muscle Invasive Bladder Cancer

  • February 10, 2022
Antengene Reports the First Patient Dosing in the P-I Trial (ERASER) of ATG-017 + Nivolumab for the Treatment of Advanced Solid Tumors

    Antengene Reports the First Patient Dosing in the P-I Trial (ERASER) of ATG-017 + Nivolumab for the Treatment of Advanced Solid Tu...

    • July 18, 2023
    PharmaShots

      PharmaShots' Key Highlights of Second Quarter 2023

      • July 3, 2023
      PharmaShots Weekly Snapshots (May 15 - 19, 2023)

        PharmaShots Weekly Snapshots (May 15 - 19, 2023)

        • May 19, 2023
        Antengene Receives the US FDA’s IND Clearance of ATG-031 for Advanced Solid Tumors or B-Cell Non-Hodgkin

          Antengene Receives the US FDA’s IND Clearance of ATG-031 for Advanced Solid Tumors or B-Cell Non-Hodgkin's Lymphoma

          • May 18, 2023
          enGene to go Public via Forbion European Acquisition Corp. SPAC Merger for ~$135M

            enGene to go Public via Forbion European Acquisition Corp. SPAC Merger for ~$135M

            • May 18, 2023
            PharmaShots Weekly Snapshots (December 27 - 30, 2022)

              PharmaShots Weekly Snapshots (December 27 - 30, 2022)

              • December 30, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.